HDT-321
Prevention of Tick-Borne Disease
Phase 1Active
Key Facts
About HDT Bio
HDT Bio is a private, clinical-stage biotech founded in 2017, advancing a transformative RNA-based delivery platform called LION™. The company's pipeline includes candidates for infectious diseases and oncology, with its lead program, HDT-321, recently receiving FDA clearance to proceed into clinical trials for tick-borne disease prevention. HDT Bio operates through a partnership and licensing model, collaborating with entities like MalarVx to expand the application of its technology into areas such as malaria vaccines. The company's strategy centers on demonstrating the broad utility of its repRNA/LION™ platform to attract further development partnerships and advance its internal candidates.
View full company profile